Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > ANG(Gene name) > Human
  • Add your favorite
  • ANG (Gene name),
  • Angiogenin (Protein name ),  ANGI_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    ANG(RNASE5);
    Protein name:
    Angiogenin;
    Alternative:
    Ribonuclease 5(RNase 5);
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Interacts with and forms a tight 1:1 complex with RNH1. Dimerization of two such complexes may occur.
    Function:
    May function as a tRNA-specific ribonuclease that abolishes protein synthesis by specifically hydrolyzing cellular tRNAs. Binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus. Angiogenin induces vascularization of normal and malignant tissues. Angiogenic activity is regulated by interaction with RNH1 in vivo.
    Subcellular Location:
    Secreted
    Protein Attributes:
    Sequence length:
    147
    Sequence:
    50:
    MVMGLGVLLL | VFVLGLGLTP | PTLAQDNSRY | THFLTQHYDA | KPQGRDDRYC | 
    100:
    ESIMRRRGLT | SPCKDINTFI | HGNKRSIKAI | CENKNGNPHR | ENLRISKSSF | 
    147:
    QVTTCKLHGG | SPWPPCQYRA | TAGFRNVVVA | CENGLPVHLD | QSIFRRP
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    UniGene:
    String:
    MIM:
    KEGG:
    Pfam:
    SMR:
    Uniprot:
     
    FOR
    ELISA Kit for Human Angiogenin
    Cat.:
    E0007h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Angiogenin
    Cat.:
    E0007m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Angiogenin
    MSDS:
    Please sign in first.
    ELISA Kit for Human Angiogenin
    Cat.:
    E0007p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Angiogenin
    Cat.:
    E0007c
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Angiogenin
    Cat.:
    U0007p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Angiogenin
    MSDS:
    Please sign in first.
    CLIA Kit for Human Angiogenin
    Cat.:
    U0007h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Angiogenin
    Cat.:
    U0007m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Angiogenin
    Cat.:
    U0007c
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human Angiogenin
    Polyclonal Antibody for Human Angiogenin
    Polyclonal Antibody for Human Angiogenin
    Cat.:
    P0007Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Angiogenin
    Cat.:
    P0007Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Angiogenin
    Monoclonal Antibody for Human Angiogenin
    Monoclonal Antibody for Human Angiogenin
    Monoclonal Antibody for Human Angiogenin
    Monoclonal Antibody for Human Angiogenin
    Monoclonal Antibody for Human Angiogenin
    Protein for Human Angiogenin
    Protein for Human Angiogenin
    Protein for Human Angiogenin
    Protein for Human Angiogenin
    Protein for Human Angiogenin

    R&D Technical Data

          12% SDS-PAGE Analysis

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤ 5.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤ 9.2%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    95

    91-101

    Plasma

    94

    90-99

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    89-99%

    91-102%

    93-103%

    90-104%

    EDTA plasma(n=5)

    89-98%

    90-103%

    91-97%

    92-102%

    heparin plasma(n=5)

    90-101%

     

    92-105%

    94-107%

    91-106%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor."
      Kurachi K. , Davie E.W. , Strydom D.J. , Riordan J.F. , Vallee B.L.
      Biochemistry24:5494-5499(1985) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    2. 2.
      "Diversifying selection of the tumor-growth promoter angiogenin in primate evolution."
      Zhang J. , Rosenberg H.F.
      Mol. Biol. Evol.19:438-445(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA];VARIANT GLU-84
    3. 3.
      Li J. , Wang H.
      Submitted (2008-09) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA]
    4. 4.
      "Cloning of human full open reading frames in Gateway(TM) system entry vector (pDONR201)."
      Ebert L. , Schick M. , Neubert P. , Schatten R. , Henze S. , Korn B.
      Submitted (2004-05) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
    5. 5.
      "NEDO functional analysis of protein and research application project."
      Wakamatsu A. , Yamamoto J. , Kimura K. , Kaida T. , Tsuchiya K. , Iida Y. , Takayama Y. , Murakawa K. , Kanehori K. , Andoh T. , Kagawa N. , Sato R. , Kawamura Y. , Tanaka S. , Kisu Y. , Sugano S. , Goshima N. , Nomura N. , more...
      Submitted (2008-01) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
      tissue: Small intestine.
    6. 6.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    7. 7.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
      tissue: Liver.
    8. 8.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 25-147;PYROGLUTAMATE FORMATION AT GLN-25;DISULFIDE BONDS
    9. 9.
      "Tissue distribution and developmental expression of the messenger RNA encoding angiogenin."
      Weiner H.L. , Weiner L.H. , Swain J.L.
      Science237:280-282(1987) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: TISSUE SPECIFICITY
    10. 10.
      "Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily."
      Saxena S.K. , Rybak S.M. , Davey R.T. Jr. , Youle R.J. , Ackerman E.J.
      J. Biol. Chem.267:21982-21986(1992) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION
    11. 11.
      "Identification of the nucleolar targeting signal of human angiogenin."
      Moroianu J. , Riordan J.F.
      Biochem. Biophys. Res. Commun.203:1765-1772(1994) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBCELLULAR LOCATION;NUCLEOLAR LOCALIZATION SIGNAL
    12. 12.
      "Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A."
      Chen C.Z. , Shapiro R.
      Proc. Natl. Acad. Sci. U.S.A.94:1761-1766(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: MUTAGENESIS OF HIS-32; GLN-36; LYS-64; ASN-92 AND GLU-132
    13. 13.
      "Superadditive and subadditive effects of 'hot spot' mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A."
      Chen C.Z. , Shapiro R.
      Biochemistry38:9273-9285(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH RNH1;MUTAGENESIS OF ARG-29 AND LYS-64
    14. 14.
      "The nuclear function of angiogenin in endothelial cells is related to rRNA production."
      Xu Z.P. , Tsuji T. , Riordan J.F. , Hu G.F.
      Biochem. Biophys. Res. Commun.294:287-292(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;SUBCELLULAR LOCATION;DNA-BINDING
    15. 15.
      "Ribonuclease inhibitor regulates neovascularization by human angiogenin."
      Dickson K.A. , Kang D.K. , Kwon Y.S. , Kim J.C. , Leland P.A. , Kim B.M. , Chang S.I. , Raines R.T.
      Biochemistry48:3804-3806(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;INTERACTION WITH RNH1;MUTAGENESIS OF 109-GLY-GLY-110
    16. 16.
      "Angiogenin-induced tRNA fragments inhibit translation initiation."
      Ivanov P. , Emara M.M. , Villen J. , Gygi S.P. , Anderson P.
      Mol. Cell43:613-623(2011) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION
    17. 17.
      "Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease."
      Acharya K.R. , Shapiro R. , Allen S.C. , Riordan J.F. , Vallee B.L.
      Proc. Natl. Acad. Sci. U.S.A.91:2915-2919(1994) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 25-147
    18. 18.
      "Molecular recognition of human angiogenin by placental ribonuclease inhibitor -- an X-ray crystallographic study at 2.0-A resolution."
      Papageorgiou A.C. , Shapiro R. , Acharya K.R.
      EMBO J.16:5162-5177(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 25-147 IN COMPLEX WITH RNH1 AND SUBUNIT
    19. 19.
      "Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth."
      Leonidas D.D. , Shapiro R. , Allen S.C. , Subbarao G.V. , Veluraja K. , Acharya K.R.
      J. Mol. Biol.285:1209-1233(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 26-147
    20. 20.
      "Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography."
      Leonidas D.D. , Chavali G.B. , Jardine A.M. , Li S. , Shapiro R. , Acharya K.R.
      Protein Sci.10:1669-1676(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 26-147 OF MUTANT GLY-141 IN COMPLEX WITH PHOSPHATE AND PYROPHOSPHATE
    21. 21.
      "Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency."
      Leonidas D.D. , Shapiro R. , Subbarao G.V. , Russo A. , Acharya K.R.
      Biochemistry41:2552-2562(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 26-147;MUTAGENESIS OF ASP-140; GLN-141 AND 143-ILE-PHE-144
    22. 22.
      "The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody."
      Chavali G.B. , Papageorgiou A.C. , Olson K.A. , Fett J.W. , Hu G. , Shapiro R. , Acharya K.R.
      Structure11:875-885(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 26-147
    23. 23.
      "Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38-41."
      Holloway D.E. , Chavali G.B. , Hares M.C. , Baker M.D. , Subbarao G.V. , Shapiro R. , Acharya K.R.
      Biochemistry43:1230-1241(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF MUTANTS ASP-68 AND ALA-104
    24. 24.
      "Three-dimensional solution structure of human angiogenin determined by 1H,15N-NMR spectroscopy -- characterization of histidine protonation states and pKa values."
      Lequin O. , Thuering H. , Robin M. , Lallemand J.-Y.
      Eur. J. Biochem.250:712-726(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: STRUCTURE BY NMR
    25. 25.
      "Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis."
      Padhi A.K. , Kumar H. , Vasaikar S.V. , Jayaram B. , Gomes J.
      PLoS ONE7:E32479-E32479(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: 3D-STRUCTURE MODELING
    26. 26.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT ALS9 ILE-64
    27. 27.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55; TRP-63 AND ILE-64;VARIANT VAL-70
    28. 28.
      "Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis."
      Wu D. , Yu W. , Kishikawa H. , Folkerth R.D. , Iafrate A.J. , Shen Y. , Xin W. , Sims K. , Hu G.-F.
      Ann. Neurol.62:609-617(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS ALS9 SER-20; ILE-41; ASN-52 AND LEU-136;CHARACTERIZATION OF VARIANTS ALS9 ILE-41; ASN-52 AND LEU-136;TISSUE SPECIFICITY
    29. 29.
      "Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis."
      Crabtree B. , Thiyagarajan N. , Prior S.H. , Wilson P. , Iyer S. , Ferns T. , Shapiro R. , Brew K. , Subramanian V. , Acharya K.R.
      Biochemistry46:11810-11818(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CHARACTERIZATION OF VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55; TRP-63 AND ILE-64;CHARACTERIZATION OF VARIANT VAL-70
    30. 30.
      "Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis."
      Gellera C. , Colombrita C. , Ticozzi N. , Castellotti B. , Bragato C. , Ratti A. , Taroni F. , Silani V.
      Neurogenetics9:33-40(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS ALS9 SER-12; SER-20; ILE-137 AND ARG-138;VARIANT VAL-70
    31. 31.
      "A novel angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy."
      Conforti F.L. , Sprovieri T. , Mazzei R. , Ungaro C. , La Bella V. , Tessitore A. , Patitucci A. , Magariello A. , Gabriele A.L. , Tedeschi G. , Simone I.L. , Majorana G. , Valentino P. , Condino F. , Bono F. , Monsurro M.R. , Muglia M. , Quattrone A.
      Neuromuscul. Disord.18:68-70(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INVOLVEMENT IN ALS9
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a KSR2 Gdf5
    Top Searches
    Ubiquitin-protein ligase Ubiquitin ELISA metalloproteinase Asprosin Tumor necrosis TRAP1A Alpha
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter